36 slides from Dr. Lal Pathlabs's earnings presentation, Oct 26, 2021
Slide 1: Cover letter to stock exchanges
October 26, 2021 The National Stock Exchange of India Limited The Bombay Stock Exchange Lim ited Exchange Plaza, Sandra Kurla Complex, 151h Floor, Phiroze Jeejeeboy Towers Sandra (E), Mumbai - 400051 Dalal Street, Mumbai - 400001 Subject: Earnings Presentation on Unaudited Financial Results (Standal
Slide 2: Q2 & H1 FY22 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q2 & H1 FY22 Results Presentation Oct 26, 2021
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 4 Overview of Dr. Lal PathLabs 5 Key Performance Highlights 7 Financials 10 Financial Highlights 11 Operating Highlights 12 Acquisition of Suburban Diagnostics 13 Management Commentary 19 Corporate Overview 20 Shareholding 34 Contact Us 35 DISCLAIMER:
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance India’s Leading & Trusted 15% 22% 200% Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend CAGR CAGR for FY 20-21 diagnostics 70+ years of experience chain in the in the field of diagnostics country with ~86% Rs. 1,137 crore PAN India ROCE Cash & Inv
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Pan-India Unique and Established integrated successful brand coverage Varied Offerings operating model 231 clinical labs Well-positioned (including National Reference Lab at Catalogue of 471 test Scalable model in one of the Established consumer Delhi and Regional panels
Slide 7: Q2 FY22 Snapshot
Q2 FY22 Snapshot 15.4% INR 498.4 Cr Revenues 28.5% 6.9 Mn Patients 13.1% INR 152.2 Cr Normalised EBITDA 33.4% 17.6 Mn Samples 10.6% INR 96.3 Cr PAT Classification: Restricted 6
Slide 8: Key Performance Highlights
Key Performance Highlights In Q2 FY22: • Revenues were higher by 15.4% Y-o-Y to Rs. 498.4 crore • Normalised EBITDA (after eliminating the impact of stock-based compensation & CSR) came in at Rs. 152.2 crore, up by 13.1% • Profit After Tax increased by 10.6% to Rs. 96.3 crore over corresponding quar
Slide 9: Non-COVID, COVID & Allied Revenue
Non-COVID, COVID & Allied Revenue Rs. Cr. Total 432 452 431 607 498 448 374 386 336 342 37 105 74 81 74 13 43 8 41 11 11 16 6 4 10 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Non COVID COVID* COVID Allied 1** COVID Allied 2*** Total Covid and Covid allied contribution at 10% in Q2 FY22, 22% in Q2 FY21 *
Slide 10: Q2 FY22 Non-COVID, COVID & Allied Revenue - Monthwise
Q2 FY22 Non-COVID, COVID & Allied Revenue - Monthwise Rs. Cr. Total 165 164 169 147 155 146 14 13 1 1 2 3 3 10 3 Jul'21 Aug'21 Sep'21 Non COVID COVID* COVID Allied 1** COVID Allied 2*** *COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dimer; ***COVID Allied 2 includes CRP
Slide 11: Financials
Financials Particulars (Rs. Cr.) Q2 FY22 Q2 FY21 Gr % FH FY22 FH FY21 Gr % Revenue 498.4 431.9 15.4% 1,105.0 697.9 58% Expenditure 357.0 304.7 774.6 522.4 EBITDA 141.5 127.3 11.2% 330.4 175.5 88% Stock based comp. & CSR cost 10.7 7.4 5.8 13.0 Normalised EBITDA 152.2 134.7 13.1% 336.3 188.5 78% Norma
Slide 12: Financial Highlights
Financial Highlights All figures in Rs. Crore Revenue Normalised EBITDA* PBT PAT 498.4 152.2 130.7 96.3 134.7 87.1 431.9 116.6 +15% +13% +11% +12% Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 Q2 FY21 Q2 FY22 *After eliminating the impact of stock based compensation, and CSR costs Financia
Slide 13: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +38 +1,552 +3,623 200 216 231 3,095 3,705 9,247 193 2,569 6,426 6,995 2,153 5,624 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 No. of Patients (Mn) No. of Samples (Mn) +43% +33% 20.3 47.7 49.7 17.6 19.4 41.8 35.
Slide 14: Acquisition of Suburban Diagnostics (SDIPL)
Acquisition of Suburban Diagnostics (SDIPL) 13
Slide 15: Strategic Rationale
Strategic Rationale West market – a strategic priority for LPL: Acquisition of Suburban Diagnostics will enable LPL to 01 scale up Revenue Suburban Diagnostics has gained strong leverage and brand recognition through the Covid 02 pandemic; Provides LPL a strong regional brand & market presence 03 Su
Slide 16: Suburban Diagnostics – At a glance
Suburban Diagnostics – At a glance Suburban Diagnostics (SDIPL) is one of Maharashtra’s premier & most trusted diagnostic company 30% 22% 20% 16% Started in 1994 with 27+ years of experience in 3 Year Revenue 3 Year patient EBITDA margin PAT margin FY21 CAGR volume CAGR FY21 the field of diagnostics
Slide 17: Financial Highlights
Financial Highlights All figures in Rs. Crore Revenue EBITDA & Margin PAT & Margin (Covid vs. Non-Covid) 294.0 57.5 47.2 167.1 159.4 25.0 76.8 20% 17.5 16% 16% 126.9 82.6 11% FY21 *H1FY22E FY21 *H1FY22E FY21 *H1FY22E Non-COVID COVID EBITDA Margin % PAT Margin % *Estimated based on management account
Slide 18: LPL+SDIPL – Consolidation in West basis FY21
LPL+SDIPL – Consolidation in West basis FY21 WEST Maharashtra LPL: Rs 158 Cr Greater Mumbai LPL+SDIPL LPL + SDIPL LPL + SDIPL Rs. 452 Cr Rs. 347 Cr Rs. 261 Cr SDIPL: Rs 294 Cr Revenue contribution Greater Mumbai Greater Mumbai will from West region to revenue to contribute become second largest go u
Slide 19: Key Highlights of the acquisition
Key Highlights of the acquisition Dr Lal Pathlabs Ltd (LPL) has signed Dr Sanjay Arora, the definitive agreement to acquire Founder of 100% equity of Suburban Diagnostic Closing is Experienced (India) Private Limited in an all cash Suburban, will The deal shall be expected within professional deal f
Slide 20: Management Commentary
Management Commentary Commenting on the results Commenting on the results Commenting on the results announcement, (Hony) Brig. Dr. Arvind announcement, Dr. Om Manchanda, announcement, Bharath Uppiliappan, Lal, Executive Chairman Managing Director Chief Executive Officer “We are happy to announce the
Slide 21: Corporate Overview
Corporate Overview
Slide 22: Vision, Mission & Values
Vision, Mission & Values VISION Customer First Be the most trusted healthcare partner, enabling healthier lives Ethics & Integrity VALUES Quality To be the undisputed market leader by providing accessible, affordable, timely and quality healthcare, Accountability diagnostics, applying insights and c
Slide 23: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities in South & West North, East & Central Indian of the markets indust
Slide 24: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations Expand 4 3 management of Geographic hospital based expansion and clinical laboratories Classification: Restricted 23
Slide 25: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city & cluster approach standards diagnostic t
Slide 26: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Logistics Lab Operations Business Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients
Slide 27: Consistent investments in R&D
Consistent investments in R&D DSIR recognized In House R&D unit R&D Collaboration with marquee Successful commercialization of with an experienced team of institutions tests research scientists and doctors Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium
Slide 28: Genevolve: The Genomics initiative
Genevolve: The Genomics initiative GENEVOLVE brings the dawn of a new era of Genomic testing! Tests are carried out using cutting edge technologies such as Genevolve: Genomics division Next Generation Sequencing focuses on Genetic testing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing among others New
Slide 29: In-house adoption of Digital Histopathology
In-house adoption of Digital Histopathology Reporting of Digital Breast cancer Panels using AI based algorithms Digital Histopathology for remote routine reporting • Enhanced access to second opinion, synchronous review of slides Opportunities • Enhanced quality of reporting created by Digital •
Slide 30: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry 100+ Quality Risk based improvement Digitally enabled Real time quality solutions control quality meetings on a assurance daily basis with implemented for monitoring quality audits framework the network partners and trainings Best in the Industry CAP Profici
Slide 31: Best in class Logistics and Supply Chain management
Best in class Logistics and Supply Chain management Real Real time time service sample monitoring tracking Control tower Real time Field Automated Cash Productivity Executive collection and route tracking process planning with clients visibility Classification: Restricted 25
Slide 32: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Auto Routing engine to dynamically allocate the booking to nearest Real time phlebo visibility to the patient available phlebotomist Variable model which grows with Real time slot confirmation to patient business volume ECG at home service launched in
Slide 33: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Company Sec
Slide 34: Key Awards & Recognition
Key Awards & Recognition Dr. Om Manchanda honoured ICICI Lombard & CNBC EY Entrepreneur of The Data Quest Technology VC Circle Healthcare and awarded as ‘Healthcare TV18 India Risk Year 2019 – Life Award 2015 – Excellence Summit 2013 – Best Personality of the Year, 2020’ Management Awards 2020 Scien
Slide 35: Shareholding as of 30th September, 2021
Shareholding as of 30th September, 2021 30.1% FIIs, FPIS & Foreign Company 10.5% 55.2% Others Promoter and Promoter Group 4.2% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well Classification: Restricted 34
Slide 36: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests